Next Investors logo grey

Victoria removes roadblocks for medicinal cannabis

Published 14-APR-2016 09:22 A.M.


2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Another day, another roadblock removed to medical cannabis acceptance with the Victorian government clearing the way for legal access in “exceptional circumstances”.

Thanks to a bill which passed Victorian parliament earlier this week, patients and their families will be able to legally access medical cannabis – with an initial focus on children with severe epilepsy.

The Victorian government had previously flagged increased access to synthetic medical cannabis trials for those suffering epilepsy – but the latest bill effectively creates a framework for patients to access medical cannabis for the first time.

At this stage, patients should be able to access medical cannabis from early 2017.

State health minister Jill Hennessy said the bill would alleviate suffering she had witnessed first-hand.

“It is absolutely heart-breaking to see families having to choose between breaking the law and watching their children suffer – and now, thanks to our ground-breaking legislation, they won’t have to,” Hennessey said in a statement.

In addition to increased access, the Victorian government will move to establish an Office of Medicinal Cannabis to help oversee manufacture and all clinical aspects of the bill framework.

As part of this push, the Victorian government will create an advisory body to help provide advice on which products would be available under the laws and other matters.

It also flagged the possibility of widening the scope of who would be able to access the products in the future.

In February the Australian senate passed a bill which essentially put medical cannabis into the same restricted class of drugs as morphine – rather than being classed as an illicit drug.

The way for a national regulator has now been paved to be set up to audit companies which wish to grow medical cannabis in Australia, extracting cannabidiol to use in medical products.

At the time, health minister Susan Ley called it the “missing link” in Australian regulation of medical cannabis products.

Previoulsy, patients had a confusing combination of ways to access medical cannabis products – some of which have been shown to help multiple sclerosis, epilepsy and some cancers.

In the past, Australians had to import products but were faced with export barriers in place in other countries.

Having a local supply of Australian made and manufactured medical cannabis products has significant potential for patients who could benefit from medical cannabis products.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.